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Female breast cancer is the most common cancer in Latin American and Caribbean (LAC)
countries and is the leading cause of cancer deaths. The high mortality-to-incidence ratio in
the regions is associated with mainly the high proportion of advanced stage diagnosis, and
also to inadequate access to health care. In this study we aimed to systematically review the
proportion of advanced stage (III-IV) at diagnosis (pas) and the five-year stage-specific sur-
vival estimates of breast cancer in LAC countries.
Methods
We searched MEDLINE, Embase, and LILACS (Latin American and Caribbean Health Sci-
ence Literature) to identify studies, in any language, indexed before Nov 5, 2018. We also
conducted manual search by reviewing citations of papers found. pas was summarized by
random effects model meta-analysis, and meta-regression analysis to identify sources of
variation. Stage-specific survival probabilities were described as provided by study authors,
as it was not possible to conduct meta-analysis. PROSPERO CRD42017052493.
Results
For pas we included 63 studies, 13 of which population-based, from 22 countries comprising
221,255 women diagnosed from 1966 to 2017. The distribution of patients by stage varied
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greatly in LAC (pas 40.8%, 95%CI 37.0% to 44.6%; I2 = 99%; p<0.0001). The heterogeneity
was not explained by any variable included in the meta-regression. There was no difference
in pas among the Caribbean (pas 43.0%, 95%CI 33.1% to 53.6%), Central America (pas
47.0%, 95%CI 40.4% to 53.8%) and South America (pas 37.7%, 95%CI 33.1% to 42.5%)
regions. For 5-year stage-specific survival we included 37 studies, comprising 28,988
women from ten countries. Seven of these studies were included also for pas. Since we
were unable to adjust for age, comparability between countries and regions was hampered,
and as expected, the results varied widely from study to study.
Conclusions
LAC countries should look to address concerns with early detection and diagnosis of breast
cancer, and wherever viable implement screening programs and to provide timely
treatment.
Introduction
In 2018, of the 18 million new cancer cases diagnosed, female breast cancer was the second
most frequent, corresponding to 11% of all cancer cases. In Latin America and the Caribbean
(LAC) breast cancer was the most common and also the leading cause of cancer related death
among women [1]. This pattern was observed previously [2] and is likely to continue in the
coming decades. Although the incidence of breast cancer in LAC countries is almost half of
that of Europe and North America, the mortality-to-incidence ratio is higher [3].
Despite most LAC countries being classified as upper-middle or high-income by the World
Bank [4], social inequality and disparities are is still high in the region [5]. This corroborates
the relative high mortality-to-incidence ratio of breast cancer observed, as the relationship
between low socioeconomic status and poor breast cancer outcomes is well-established [6].
Among the 11 countries from LAC that contributed to the third global surveillance of trends
in cancer survival (CONCORD-3), six reported age-standardized five-year net survival of
breast cancer lower than 80% between 2010 and 2014, among them, were populous countries
including Brazil and Colombia [7].
The low overall survival estimates are mainly related to the high proportion of women diag-
nosed with advanced disease, but also to lower access to proper treatment in LAC countries. In
2013, The Lancet Oncology Commission identified the following goal for LAC: “Avoid late
diagnosis of stage IV cancer to reduce morbidity, mortality, and financial cost”. Suggestions to
achieve this goal include optimizing early detection; developing targeted screening programs;
implementing clinical early diagnosis programs; and optimizing the treatment of primary can-
cer [8]. Some studies have compiled the proportions of advanced stage diagnosis [9,10], but, to
our knowledge none has assessed this systematically. Stage-specific survival, which may repre-
sent an important tool to examine the care each cancer stage is receiving, also has not been
studied systematically.
With this review, we intended to systematically assess the distribution of stage at diagnosis
of breast cancer in LAC, examining the proportion of advanced disease diagnosis, and possibly
the stage-specific survival data from the region. In this way, we hope to provide information
for breast cancer control and future guidance to all key stakeholders in the countries in the
region.
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Methods
Search strategy and selection criteria
For this systematic review with meta-analysis, we developed a study protocol (S1 File) follow-
ing the recommendations of PRISMA guidelines [11] (S1 Table) which was registered in
PROSPERO under the number CRD42017052493. There was no funding source for this
study. On November 5, 2018, we searched MEDLINE, Embase and Latin American, and
Caribbean Health Sciences Literature (LILACS) to identify studies reporting the stage at diag-
nosis and/or stage-specific survival probability of breast cancer in LAC countries. For this,
we used the terms “breast cancer” (Medical Subject Heading (MeSH) and synonyms) and the
names of all Latin American and Caribbean countries (as defined by the United Nations)
[12], and demonyms (e.g., Argentina OR Argentinian) (S2 File). We conducted manual
searches in the reference list of included studies and systematic reviews, PAHO Virtual
Health Library regional databases, Scientific Electronic Library Online regional databases
and MedCarib. Gray literature was considered for inclusion if no peer-reviewed study was
included for the country or region of the country. No restrictions were imposed with respect
to the setting of diagnosis or treatment, whether it was private or public, or the language of
the publication.
Study selection was conducted in two steps, (i) title and abstract and (ii) full text, in dupli-
cate by two authors (LLPL and PHRFA). Conflicts over the inclusion of potential studies in the
review were resolved by consensus between the two authors (LLPL and PHRFA). Rayyan
application was used for title and abstract screening (https://rayyan.qcri.org) [13]. Observa-
tional studies evaluating women living in LAC countries with confirmed diagnosis of invasive
breast cancer were considered eligible. For survival probability, clinical trials were also consid-
ered eligible. We excluded studies evaluating: LAC women living in other regions (sometimes
referred to latinas); patients diagnosed with Paget’s disease or Phyllodes tumor or which gave
results including such patients; lactating and pregnant women; and exclusively men. Consider-
ing that the incidence of male breast cancer is very low, studies that involve both sexes were
not excluded even if results were not presented separately. Studies with a smaller population
from the same location/registry of an included study were excluded because of the potential
to include repeated patients. Multi-country studies not reporting results by country were
excluded. We also excluded studies reporting only survival probability of early stages that
included in situ cases and studies that reported stage at diagnosis only as aggregate categories
including in situ stage (e.g.; early stage: 0-IIa). For the survival probability outcome we
excluded studies reporting only hazard ratios, and for stage at diagnosis we excluded studies
evaluating specific disease stages.
Data extraction and quality assessment
Data extraction and quality assessment were performed in duplicate by two authors (LLPL and
DPM) with discordances resolved by consensus among them. We used a specially designed
spreadsheet to collect information regarding: country; study design; study setting (name of
studied health services; name of population-based registry); if the study included stage at diag-
nosis or survival probability outcomes or both; number of included patients; year of diagnosis;
age at diagnosis; menopausal status; histology type; tumor grade; hormonal receptor status;
HER-2 status; molecular subtype; and race. For studies included for stage at diagnosis we col-
lected the staging criteria; the number of patients who presented in the different stages as
given by the study authors, i.e., using the most disaggregated Tumor, Lymph Node, and Metas-
tasis (TNM) staging (Ia, Ib, . . ., IV), TNM or Manchester stages I, II, III and IV, TNM or
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Manchester aggregated stages (I-II, III-IV, I-IIa, IIb-IV), or SEER staging (localized, regional,
distant). For studies included for survival probability we collected the starting date of survival
analysis; if overall survival, disease specific survival or both were provided; the survival proba-
bility with standard error or confidence interval; the number of individuals at risk and number
of events; the method for survival analysis (e.g., Kaplan Meier), and the information regarding
staging classification as with the stage at diagnosis outcome.
For quality assessment of studies reporting stage at diagnosis we used the tool developed by
Elm et al. [14] and adapted by Jedy-Agba et al. [15]. For quality assessment of the studies
reporting survival probability we adapted this tool accounting for the potential sources of bias
in longitudinal studies exemplified by Chubak et al. [16] and items of The Newcastle-Ottawa
Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses [17]. In both
cases, we evaluated three domains: selection bias, information bias, and other factors related to
stage at diagnosis/survival analysis, such as age and tumor grade, with more value given to
selection and information bias items. The quality score ranged from 0–28 (low to high) in both
scales (S2 and S3 Tables). If a study reported both stage at diagnosis and survival rate, it was
evaluated separately in each tool.
Data analysis
For stage at diagnosis, we used R package “meta” to pool the primary outcome with a random
effects model (https://github.com/guido-s/meta http://meta-analysis-with-r.org) [18,19]. The
outcome was the percentage (pas) of breast cancer diagnosed in stages III-IV which was calcu-
lated as pas = (nas/n)
�100, where nas is the number of patients presented at advanced stages and
n is the number of staged patients. We considered between-study heterogeneity present when
the P value of the Cochran’s Q test was<0.1 and I2 statistic was >50%. To examine potential
sources of heterogeneity, study-specific estimates were stratified by relevant variables and a
meta-regression analysis was performed to identify correlates of percentage of advanced stage
disease. Study-level determinants of advanced stage disease are expressed as absolute differ-
ences (AD) in the percentage of patients with advanced stage disease (pas). Potential publica-
tion bias was estimated with the Egger’s test.
The primary outcome for stage-specific survival was the five-year all-cause survival of
patients diagnosed with invasive breast cancer. Secondary outcomes were cause-specific sur-
vival probability and global survival at any time. Survival probability outcomes may be from
any date (diagnosis, start of treatment, first consultation, etc.). Since the large majority of stud-
ies did not report the number of patients at risk and the number of events, a requirement for
survival probability meta-analysis, we were unable to perform meta-analysis and meta-regres-
sion for this outcome. Consequently, the survival probability outcomes were described as the
study authors provided it (percentage with or without variance).
Results
After duplicates removal, 4,957 records had their titles and abstracts assessed, resulting in 513
full-text studies that were assessed for eligibility. The complementary search yielded 79 docu-
ments that were assessed for eligibility. We finally included 95 studies (Fig 1), 46 studies
assessed breast cancer stage-specific survival in 12 countries, and 63 assessed breast cancer
stage at diagnosis in 22 countries (14 studies assessed both). For both outcomes, most studies
consisted of consecutive case series, conducted in public facilities with individuals between 40
and 59 years old diagnosed between 2000 and 2009. In the five studies that included men, male
population represented 0.3% to 0.7% of the sample [20–24]. For countries we did not find
peer-reviewed studies we searched for epidemiological/registry reports and Ecuador was the
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only country we could identify and include reports [25–27]. We also included a cancer hospital
registry report from a region of Peru for which we did not include a peer-reviewed study [28].
As for the quality score, in studies included for the outcome of stage at diagnosis, most patients
participated on studies from intermediate to low quality scores (15.5 to 18.8). (Table 1 and S2
Table). In studies included for survival probability, most patients participated on high scoring
studies (>20.5) (Table 1 and S3 Table). Both scores ranged from 0 to 28. Study references are
given in the Supporting Information (S3 File).
The 63 studies assessing the stage at diagnosis comprised 263,515 patients, 84.0% with
known stage at diagnosis. Sample sizes ranged from 59 to 137,593 (median 345). Four studies
used a staging system other than TNM and in seven studies the staging system was not
reported (Table 1 and S4 Table). The distribution of patients by stage varied greatly in LAC
(S5 Table). In studies that reported stage IV percentage, this varied from approximately 1% in
one study from Argentina with 4041 women diagnosed between 2010 and 2012 and one study
from Venezuela with 179 women diagnosed between 1999 and 2007, to 26% in one study from
Fig 1. Study selection flowchart.
https://doi.org/10.1371/journal.pone.0224012.g001
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Table 1. Study characteristics.
Survival Stage at presentation
Studies Patients with breast
cancer
Patients with known breast
cancer stage (%)
Studies Patients with breast
cancer
Patients with known breast
cancer stage (%)
Total 46 34,282 30,861 (90.0) 63 263,515 221,255 (84.0)
Region and country
Caribbean
Bahamas 1 270 134 (46.6)
Barbados 1 222 222 (100.0)
Cuba 6 5,159 4,761 (92.3) 6 3,998 3,580 (89.5)
Haiti 1 525 127 (24.2) 1 525 445 (84.8)
Jamaica 1 199 184 (92.5)
Puerto Rico 1 985 867 (88.0)
Trinidad and Tobago 2 4,130 3,458 (83.7)
Central America
Costa Rica 2 2,683 2,326 (86.7) 1 2,462 2,105 (85.5)
Honduras 1 685 653 (95.3)
Mexico 9 13,198 11,854 (89.8) 10 14,815 13,978 (94.4)
South America
Argentina 3 1,882 1,828 (97.1) 6 8,454 7,344 (86.9)
Brazil 8 4,030 3,769 (93.5) 3 188,645 154,889 (82.1)
Chile 3 1,447 1,318 (91.1) 2 23,357 21,477 (92.0)
Colombia 4 1,805 1,662 (92.1) 11 6,038 5,405 (89.5)
Ecuador 1 21 21 (100) 3 2,438 2,079 (85.3)
French Guiana 1 269 239 (88.8)
Guyana 1 499 445 (89.2)
Paraguay 1 80 80 (100.0)
Peru 2 354 147 (41.5) 5 4,178 2,514 (61.0)
Suriname� 1 419 351 (83.8)
Uruguay 1 1,311 1,185 (90.4) 2 222 216 (97.3)
Venezuela 6 1,867 1,863 (99.8) 2 625 590 (94.4)
Study design (sampling)
Convenience 4 7,177 6,422 (89.5) 2 1,161 1,097 (94.5)
Consecutive 31 22,619 20,195 (89.3) 47 249,196 209,245 (84.0)
Population-based 3 1,640 1,602 (97.7) 13 13,099 10,869 (83.0)
Unclear 8 2,846 2,642 (92.8) 1 59 54 (91.5)
Type of facility
Private† 10 6,510 5,635 (86.6) 7 3,925 3,520 (89.7)
Public and Private 2 3,207 2,831 (88.3) 11 11,685 10,016 (85.7)
Public 30 22,085 20,081 (90.9) 37 237,839 199,006 (83.7)
Not reported in original
study
4 2,480 2,314 (93.3) 8 10,066 8,713 (86.6)
Age at diagnosis (years)‡
<40 years 1 107 107 (100.0)
�40 to <60 years 41 30,072 26,781 (89.1) 51 183,937 155,502 (84.5)
�60 years 3 1,703 1,573 (92.4) 5 962 766 (79.6)
Not reported in original
study
2 2,507 2,507 (100) 6 78,509 64,880 (82.6)
Year of diagnosis¶
Before 1999 23 15,987 14,555 (91.0) 12 60,528 49,533 (81.8)
(Continued)
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Costa Rica with 2462 women diagnosed between 1995 and 2000 and 29% in one study from
Haiti with 525 women diagnosed between 2013 and 2017. This study reported the highest pro-
portion of stage III-IV diagnosis, 84.3%; the lowest proportion (9.7%) was observed in one
study with 230 women diagnosed between 2001 and 2016 in Mexico (Fig 2). Consequently,
there was considerable heterogeneity in the proportion of patients diagnosed with stage III-IV
(pas 40.8%, 95%CI 37.0% to 44.6%; I
2 = 99%; p<0.0001) (Fig 3).
There was no difference between regions, however there was a tendency of lower propor-
tion of patients diagnosed with stage III-IV in South America (pas 37.7%, 95%CI 33.1% to
42.5%; I2 = 99%; p<0.0001) and the highest in the Caribbean (pas 43.0%, 95%CI 33.1% to
53.6%; I2 = 98%; p<0.01) (Fig 3). Publication bias was difficult to analyze due to the high het-
erogeneity (S1 Fig). As a post-hoc analysis, we conducted a meta-analysis including patients
diagnosed with stage IIb. The overall estimate of the proportion of patients diagnosed with
stage IIb-IV was 64.0% (95%CI 57.0% to 70.4%; I2 = 98%; p<0.01). There was no difference
between regions and no tendency was observed (Fig 4).
Adjusted meta-regression did not reveal any association between the proportion of stage
III-IV diagnosis and any of the available variables. The adjusted meta-regression revealed that
Table 1. (Continued)
Survival Stage at presentation
Studies Patients with breast
cancer
Patients with known breast
cancer stage (%)
Studies Patients with breast
cancer
Patients with known breast
cancer stage (%)
2000–2009 21 17,278 15,687 (90.8) 44 194,787 164,689 (84.5)
2010 or after 1 525 127 (24.2) 7 8,200 7,033 (85.8)
Not reported in original
study
1 492 492 (100)
Staging methods
Clinical and imaging 8 8,213 7,553 (92.0) 7 6,002 5,749 (95.8)
Clinical only 3 662 662 (100)
Not reported in original
study||
35 25,407 22,646 (89.1) 53 257,513 215,506 (83.7)
Staging classification
TNM 39 25,249 22,723 (90.0) 52 250,429 219,990 (83.9)
Manchester/SEER/
NCCN
3 7,006 6,252 (89.2) 4 5,979 5,107 (85.4)
Not reported in original
study||
4 2,027 1,886 (93.0) 7 7,107 6,158 (86.6)
Study quality scores††
�15 (lowest quality) 7 6,936 6,550 (94.4) 9 8,833 6,587 (74.6)
15.5–18.5 9 5,232 5,030 (96.1) 24 228,308 191,045 (83.7)
19–20.5 11 7,056 6,491 (92.0) 18 18,737 16,402 (87.5)
>20.5 (highest quality) 19 15,058 12,790 (84.9) 12 76,37 7,221 (94.6)
Data are n or n (%). Study references are given in the Supporting Information (S3 File). TNM, Tumor, Lymph Node, and Metastasis staging system; SEER, Surveillance,
Epidemiology, and End Results Summary Stage (localized, regional, distant).
� SUR-van Leeuwaarde (2011) provided tumor size, T3/4 were considered as a proxy for stages III/IV.
† Includes non-profit organizations.
‡ Mean or median age at breast cancer diagnosis. If only age categories were provided, mean or median age was estimated from the midpoint and the reported number
in each category.
¶ Middle year of the time interval of patient recruitment or diagnosis.
†† Categories represent quartiles of the overall score distribution.
https://doi.org/10.1371/journal.pone.0224012.t001
Stage at diagnosis and stage-specific survival of breast cancer in Latin America and the Caribbean
PLOS ONE | https://doi.org/10.1371/journal.pone.0224012 October 16, 2019 7 / 17
consecutive case series presented a higher proportion of stage IIb-IV diagnosis than popula-
tion-based studies (Absolute Difference, AD 49.5, 95%CI 15.5% to 83.5%). Studies conducted
in private settings, and studies conducted with older patients (�60 years old), presented a bor-
derline lower proportion of stage IIb-IV diagnosis, when compared to, respectively, studies
conducted in private settings and studies conducted with patients between 40 and 59 years of
age (Table 2).
The 46 studies assessing survival probability comprised 34,282 patients diagnosed from
1966 to 2017, 90.0% with known disease stage. Sample sizes ranged from 21 to 4,902 (median
345). Thirty-five studies used the Kaplan-Meier method to estimate survival probability, nine
studies used the actuarial method and one study from Cuba did not report the survival analysis
method [29]. Thirty-seven studies considered deaths from any cause and nine considered dis-
ease-related deaths. Most included studies (67%) were hospital-based studies in which conse-
cutive patients were followed-up for a determined period of time, hence studies populations
and settings varied greatly. Only four studies were population-based, three from Cuba
[23,30,31] and one from Costa Rica [22]. For 5-year stage-specific survival we included 37
Fig 2. Study-specific percentage of patients by stage at presentation. Percentage of T3/T4 cancers were used as proxy of stages III/IV for SUR-van
Leeuwaarde (2011). Localized, regional and distant disease were considered as stages I-II, III and IV for CRI-Ortiz-Barboza (2011), CUB-Garrote
(2011), and PRI-Ortiz (2010). Recruitment or diagnosis years: BHS-Mungrue (2016) A!C = 2009!2011; BRA-Thuler and Mendonc¸a (2005)
A = 1990–1994 B = 1995–2002; CHL-Prieto (2011) A!J = 2000!2011; HND-Muñoz (2011) A = 1999 B = 2000–2004 C = 2005–2009; MEX-Ortega-
Cervantes (2013) A!E = 2006!2010; MEX-Arce-Salinas (2012) A = 2008 B = 2009. Study references are given in the Supporting Information (S3 File).
https://doi.org/10.1371/journal.pone.0224012.g002
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Fig 3. Forest-plot of percentage of stage III-IV breast cancer at diagnosis, by region of Latin America and
Caribbean. Percentage of T3/T4 cancers were used as proxy of stages III/IV for SUR-van Leeuwaarde (2011). Regional
and distant disease were considered as stages III and IV for CRI-Ortiz-Barboza (2011), CUB-Garrote (2011), and
PRI-Ortiz (2010). The study GUY-Taioli (2010) was not included because it provided the proportion of patients
diagnosed with stages I-III (93%) and stage IV (7%). Recruitment or diagnosis years: BHS-Mungrue (2016)
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A!C = 2009!2011; BRA-Thuler and Mendonc¸a (2005) A = 1990–1994 B = 1995–2002; CHL-Prieto (2011)
A!J = 2000!2011; HND-Muñoz (2011) A = 1999 B = 2000–2004 C = 2005–2009; MEX-Ortega-Cervantes (2013)
A!E = 2006!2010; MEX-Arce-Salinas (2012) A = 2008 B = 2009. Study references are given in the Supporting
Information (S3 File).
https://doi.org/10.1371/journal.pone.0224012.g003
Fig 4. Forest-plot of percentage of stage IIb-IV breast cancer at diagnosis, by region of Latin America and Caribbean. Recruitment or diagnosis
years: BHS-Mungrue (2016) A!C = 2009!2011; HND-Muñoz (2011) A = 1999 B = 2000–2004 C = 2005–2009; MEX-Ortega-Cervantes (2013)
A!E = 2006!2010; MEX-Arce-Salinas (2012) A = 2008 B = 2009. Study references are given in the Supporting Information (S3 File).
https://doi.org/10.1371/journal.pone.0224012.g004
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Table 2. Meta-regression results: Analysis of predictors of advanced stages breast cancer diagnosis.
Variables Stages III-IV Stages IIb-IV�
Patients, n Unadjusted analysis Adjusted analysis Patients, n Unadjusted analysis Adjusted analysis
AD (%) 95% CI AD (%) 95% CI AD (%) 95% CI AD (%) 95% CI
Region
Caribbean 8944 0 (Ref) 0 (Ref) 1153 0 (Ref) 0 (Ref)
Central America 16486 4.2 -6.5 to 14.8 0.0003 -14.7 to 14.7 6940 1.5 -15.3 to 18.4 -20.3 -50.3 to 9.7
South America 193787 -4.9 -13.9 to 4.1 -9.8 -24.0 to 4.5 6977 -1.5 -18.3 to 15.4 -16.4 -47.2 to 14.5
Study type (sampling)
Population-based 10478 0 (Ref) 0 (Ref) 837 0 (Ref) 0 (Ref)
Consecutive 207588 1.9 -7.4 to 11.1 11.3 -3.9 to 26.4 14233 13.2 -2.2 to 28.7 49.5 15.5 to 83.5
Convenience 1097 6.9 -16.4 to 30.2 8.3 -19.1 to 35.7 0
Unclear 54 -10.3 -44.1 to 23.4 -26.8 -65.4 to 11.8 0
Type of provider
Public 198675 0 (Ref) 0 (Ref) 8168 0 (Ref) 0 (Ref)
Private† 3520 -7.9 -19.9 to 4.2 -11.1 -24.3 to 2.1 2063 -9.7 30.9 to -28.3 -22.4 -44.3 to -0.5
Public and private 10016 -6.8 -16.8 to 3.2 4.0 -12.4 to 20.4 257 -28.7 -63.7 to 6.3 75.1 -5.1 to 55.2
Not reported in original study 7006 -9.3 -20.8 to 2.2 -13.1 -26.6 to 0.4 4582 -4.9 -19.8 to 10.1 -4.5 -20.9 to 11.9
Age at diagnosis (years) ‡
<40 107 0 (Ref) 0 (Ref) 0
�40 to <60 153464 8.6 -22.7 to 40.0 16.9 -19.3 to 53.0 14159 0 (Ref) 0 (Ref)
�60 766 -5.0 -39.0 to 29.0 -1.0 -38.7 to 36.7 383 -25.3 -48.7 to -1.9 -45.8 -91.4 to -0.3
Not reported in original study 64880 5.0 -27.0 to 37.0 17.5 -20.5 to 55.6 528 26.6 -5.3 to 58.5 17.7 -16.6 to 52.0
Year of diagnosis (year) ¶
Before 1999 49533 0 (Ref) 0 (Ref) 1512 0 (Ref) 0 (Ref)
2000–2009 162651 1.1 -8.3 to 10.5 -1.0 -11.74 to 9.8 11386 15.3 -5.4 to 36.0 -12.7 -41.9 to 16.6
2010 or after 7033 -2.9 -17.4 to 11.5 -2.7 -20.2 to 14.7 2172 3.6 -24.0 to 31.1 -27.5 -69.1 to 14.1
Staging classification
TNM 208397 0 (Ref) 0 (Ref) 15070
Other (Manchester, SEER, NCCN) 5107 -0.001 -15.4 to 15.4 -10.4 -30.2 to 9.4 0
Not reported in original study 5713 10.9 -2.0 to 23.9 -7.0 -25.2 to 11.2 0
Staging methods
Clinical and imaging 5803 0 (Ref) 0 (Ref) 633 0 (Ref) 0 (Ref)
Clinical 0 0
Unclear 213414 -6.2 -17.1 to 4.8 -2.1 -22.5 to 18.4 14437 -2.7 -21.8 to 16.4 -22.8 -52.3 to 6.7
Study quality scores ||
>20.5 (highest quality) 7275 0 (Ref) 0 (Ref) 890 0 (Ref) 0 (Ref)
19–20.5 16152 -3.5 -14.2 to 7.2 -0.2 -18.7 to 18.4 4568 1.1 -18.2 to 30.4 -4.2 -19.2 to 10.8
15.5–18.5 189648 -7.5 -17.0 to 2.1 -10.2 -27.9 to 7.4 9612 6.0 -12.2 to 24.3
�15 (lowest quality) 6142 3.8 -9.6 to 17.3 12.2 -11.5 to 36.0
T3/4 were considered as a proxy for stages III/IV. Regional and distant diseases were considered as stages III and IV, respectively. Inoperable locally advanced disease
was considered as stage III. AD, Absolute difference; CI, Confidence Interval; TNM, Tumour, Lymph Node, and Metastasis staging system; SEER, Surveillance,
Epidemiology, and End Results Summary Stage; NCCN, National Comprehensive Cancer Network classification.
�Post-hoc analysis.
† Includes non-profit organizations.
‡ Mean or median age at breast cancer diagnosis. If only age categories were provided, mean or median age was estimated from the midpoint and the reported number
in each category.
¶ Middle year of the time interval of patient recruitment or diagnosis.
|| Categories represent quartiles of the overall score distribution.
https://doi.org/10.1371/journal.pone.0224012.t002
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studies, comprising 28,988 women from ten countries. Seven of these studies were included
also for pas. Study-specific details and results are given in the Supporting Information (S6 and
S7 Tables).
Discussion
In this systematic review, we used two markers, the proportion of advanced disease at diagno-
sis and stage-specific survival, in an attempt to characterize the extent of breast cancer control
in LAC countries. With data from 221,255 women from 22 countries diagnosed from 1966 to
2017, we revealed that in these regions nearly 41% women were diagnosed in stages III-IV.
The marked heterogeneity of the meta-analysis was not explained by any variable included in
the meta-regression. The post hoc analysis with data from 15,070 women from nine countries
revealed that 64% were diagnosed in stages IIb-IV. The high heterogeneity in this analysis was
explained by the type of study, with studies that used consecutive sampling presenting a
higher proportion of late-stage diagnosis than population-based studies. Only four popula-
tion-based studies with 837 women were included, and of those, two were the single represen-
tatives of their countries (Barbados [32] and Bahamas [33]), and the other two were one of
two studies included from Argentina [34] and Cuba [30]. Other variables likely to be related
to the stage at diagnosis, such as school years, socioeconomic status and race, could not be
evaluated because few studies reported them to allow comparability. Low economic status has
been related to late stage diagnosis in low- and middle-income [35] and high-income coun-
tries [36].
The high percentage of diagnosis in advanced stages in LAC contrasts sharply to the
proportions of 8.3% to 23.5% of advanced stage (III-IV) diagnosis among women of Western
European countries [37]. This points out to the low coverage of screening and early detec-
tion practices in the region. According to the World Health Organization, from 30 LAC
countries that responded to the Cancer Country Profile survey in 2014, 19 reported having
established cancer control programs or strategies, and of those, 18 stated that clinical breast
examination is generally available at the public primary health care level, and 10 reported
that mammography was available as well [38]. In this review, only one study assessed the
effect of a breast cancer screening program. Maffuz-Aziz et al. [39] showed that 83% of
women from a screening program from Mexico City were diagnosed with stages 0-IIA ver-
sus 36% of women who did not participate on the program. In Mexico, national health sur-
veys revealed low coverage of annual clinical breast exam, no higher than 55%, and the very
low annual mammography coverage of 21%. Low mammography screening coverage has
been reported in many LAC countries [40], [41]. In general, lower economic strata, no
enrollment in social security and lower educational levels were associated with lower early
detection practices [42].
A survey conducted in 2006 by the Latin American and Caribbean Society of Medical
Oncology (SLACOM) in 12 countries with breast cancer specialists revealed that 62% of
them reported a delay greater than three months between the suspicion of cancer and a mam-
mogram or clinical exam in their country [43]. Delays between suspicion and diagnosis of
breast cancer have been related to late stage diagnosis and consequently poorer survival [44].
Studies from Brazil [45] and Mexico [46] showed delays between presentation to a doctor
and diagnosis of 6–7 months, and 4–5 months in Peru [47]. In a study from Paraguay
included in the review, patients of different types of cancer took a median of nine months to
seek medical attention, and it took a median of six months to diagnose their disease [48]. A
study from Colombia showed a median time between first consultation and diagnosis of 90
days [49].
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As for stage-specific survival, we could compile results from 34,282 patients from 12 coun-
tries, and the results varied greatly across studies. The absence of age and the start date of
patient follow-up prevented us to pursue meaningful statistical analysis and meta-analysis.
Rather descriptive information extracted from each study are provided in the Supporting
Information (S7 Table). In addition, most studies reporting stage-specific survival were hospi-
tal-based consecutive case series, and our sample included very few population-based studies.
In developing countries, longer times between diagnosis and start of treatment remain a
challenge [50] in addition to long time delays between case suspicion and diagnosis [45–
47,49,51]. In the survey by SLACOM, treatment initiation delay was not reported as a problem
in participant LAC countries, as most cancer specialists reported the majority of breast cancer
patients starting treatment in less than three months from definitive diagnosis [43]. In Brazil,
treatment delay was identified as an important issue and a law was passed in 2012 establishing
a maximum of 60 days between histopathological confirmation and the start of treatment. The
effect of this law was not assessed for breast cancer; however, for gynecological cancers only a
small difference was reported between waiting times before and after the law was implemented
[52]. Longer times between breast cancer surgery and adjuvant therapy have been reported to
negatively affect survival [53]. One study from Brazil included in the review showed that each
month of delay between surgery and the first adjuvant treatment increased the risk of death by
30% [54]. This is also a concern that needs to be addressed along with shortening the time peri-
ods between suspicion of breast cancer and diagnosis.
In this review, we used a broad search strategy and conducted in depth manual searches to
gather the existing information about stage at diagnosis of more than 200,000 women with
breast cancer in LAC. In spite of this, our analysis has a number of significant limitations.
First, we were unable to find articles or reports from 27 countries. Second, for stage-specific
survival estimates, we gathered information of more than 30,000 women, but even fewer coun-
tries were represented. Also, the studies did not provide the detailed classification of tumor
and lymph node of their patients (eg., T1b, L1 etc), so we were unable to standardize the stage
grouping considering the most recent TNM staging manual [55]. This would be important as
patients then classified as early stage could have been reclassified as late stage, correcting the
potential underestimation of the percentage of late stage diagnosis. As for stage-specific sur-
vival, it is known that stage migration affects survival, as patients with better prognosis migrate
to a worst prognosis group, survival increases—the so-called Will Rogers phenomenon [56].
In addition, we were unable to compare survival estimates because it was not possible to
adjust the results for age, and also because of the great heterogeneity in settings and patient
case mixes in our study sample, that prevented comparability across studies. Fifth, very few
population-based studies were included in our study sample. Lastly and most importantly, the
great majority of the studies did not provide any information of ethnic distribution of their
populations and of their socioeconomic statues and crucially of the kinds of health services
(e.g., breast cancer screening) which were available to the patients included in our sample.
LAC countries vary enormously by sociodemographic characteristics but even more so by the
type and quality of their health care system and its financing.
LAC countries face the surge of chronic non-communicable diseases in the context of
largely fragmented health systems and substantial socioeconomic inequalities [57]. Breast can-
cer is the leading cause of cancer death among women in the region and thus should receive
considerable attention from local governments. In this review, we point to the large proportion
of advanced disease diagnosis in the region. LAC countries should address concerns with early
detection and diagnosis of breast cancer, and when financially sustainable implement appro-
priate screening and treatment programs.
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